Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter Study With Open-Label and Randomized Double-Blind Placebo-Controlled Withdrawal Phases to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms Who Are Clinically Stable and Taking Stable Doses of Atypical Antipsychotic Medication.

Next Previous
Trial Profile

A Phase 2, Multicenter Study With Open-Label and Randomized Double-Blind Placebo-Controlled Withdrawal Phases to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms Who Are Clinically Stable and Taking Stable Doses of Atypical Antipsychotic Medication.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Shire

Most Recent Events

  • 09 May 2012 Results presented at the 165th Annual Meeting of the American Psychiatric Association.
  • 09 May 2012 Results presented at the 165th Annual Meeting of the American Psychiatric Association.
  • 02 May 2011 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top